Real World Study of VIEKIRAX (ombitasvir/paritaprevir/ritonavir) and EXVIERA (dasabuvir) With Or Without Ribavirin In Patients With Chronic Hepatitis C Virus Infection.

Trial Profile

Real World Study of VIEKIRAX (ombitasvir/paritaprevir/ritonavir) and EXVIERA (dasabuvir) With Or Without Ribavirin In Patients With Chronic Hepatitis C Virus Infection.

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Nov 2016

At a glance

  • Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms AMBER
  • Most Recent Events

    • 09 Sep 2016 Status changed from recruiting to completed, according to results published in the Alimentary Pharmacology and Therapeutics.
    • 09 Sep 2016 Results published in the Alimentary Pharmacology and Therapeutics.
    • 17 Apr 2016 Preliminary results (n=209) of the predictors of hepatic de-compensation, presented at The International Liver Congress™ 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top